Omid Farokhzad

Chief Executive Officer, Chair at Seer

Board

Since February 2018

Age

55 years

Education

Holds an M.A. and M.D. from Boston University and an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management.

Tenure

Has been involved with SEER since March 2017 as a board member, co-founded the company, served as Chief Executive Officer since February 2018, became Chair in September 2020, and held the position of President from September 2022 to November 2023.

Also at Seer

David Horn

President, Chief Financial Officer

About

Omid Farokhzad, M.D., has been a transformative force at SEER, having co-founded the company and contributed significantly to its strategic direction since joining as a board member in March 2017.

During his illustrious career, he has combined his strong academic background with extensive industry experience. He earned an M.A. and M.D. from Boston University and an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management, which laid the foundation for his dual expertise in science and business.

Before dedicating his primary focus to SEER, he had an accomplished tenure at Harvard Medical School, where he directed the Center for Nanomedicine at Brigham and Women’s Hospital. This period emphasized his commitment to advancing healthcare and biomedical innovation.

At SEER, his leadership journey is marked by his role as Chief Executive Officer beginning in February 2018, his appointment as Chair in September 2020, and his period as President from September 2022 to November 2023. His visionary and multifaceted approach has driven significant contributions to the company's growth and evolution in the competitive biotechnology landscape.

$SEER Performance Under Omid Farokhzad

Past Roles

Organization	Role	Date Range	Details
SEER, Inc.	President	September 2022 - November 2023	Former role at SEER
Dynamics Special Purpose Corp.	Executive Chair	May 2021 - June 2022	N/A
Harvard Medical School	Professor	September 2004 - February 2018	Directed the Center for Nanomedicine at Brigham and Women’s Hospital
BIND Therapeutics	Co-founder	N/A	Later acquired by Pfizer Inc.
Selecta Biosciences, Inc.	Co-founder / Former Director	N/A	Clinical-stage biotechnology company
Tarveda Therapeutics, Inc.	Co-founder	N/A	Clinical-stage biopharmaceutical company

External Roles

Organization	Role	Date Range
Senti Biosciences	Board Member	N/A
Privately-held Companies	Board Member	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$600,500	Annual	After March 2023 merit increase (4.4% increase from $575,484)
401(k) Plan Matching Contributions	$2,500	Annual	Fixed contribution
Reimbursement of Commuting Costs	$88,532	Annual	Fixed reimbursement for commuting costs
Gross-Up Allowance	$70,657	Annual	Fixed gross-up allowance

Performance Compensation

Data from FY 2023

Annual Cash Incentives

Metric	Target/Value	Additional Details
Target Bonus Percentage	85% of base salary	Bonus based on corporate objectives: Financial (20%), Commercial (30%), R&D (40%), Organizational (10%)
Actual Bonus Payout	$423,653	Represents 83% of the target bonus payout

Equity Awards

Component	Units/Options	Grant Date Fair Value	Performance Threshold	Vesting Schedule
RSUs	402,000 units	$1,845,180	No specific performance condition provided	Vesting schedule not detailed
Stock Options	650,000 options	$2,170,350	Must achieve 150% of the grant date price: average price target of $6.89 over 20 trading days	7-year performance period, expiring on 02/15/2030 if conditions are not met